miReven
miReven is a biopharmaceutical company focused on developing mRx-7 as a new cancer therapy. The world of RNA-based therapeutics is an entirely new clinical treatment
Our Science
mRx-7 is a synthetic small double stranded RNA (dsRNA) chemically modified mimic of microRNA-7 (miR-7) that we have designed, which is a potent inhibitor of…
Investors
miReven welcomes new partnerships Please contact us for information about investing in our company
microRNA replacement therapy
microRNAs are tiny molecules that are encoded in the DNA within our cells. They are responsible for controlling expression of genes that dictate how the cell behaves, including deciding when to divide or move. In some cancers the amount of
A novel approach for treating cancers
Recent News
miReven scientists awarded an Australian competitive NHMRC Development grant for 2022-23
New Award – miReven scientists awarded an Australian competitive NHMRC Development grant for 2022-23. Prof Leedman and the team were successful in being awarded a
mRx-7 presented at the American Association for Cancer Research
At a virtual conference hosted by the American Association for Cancer Research (AACR), April 10-15 2021, preliminary results of mRx-7 were presented by Prof Peter
mRx-7 and microRNAs in cancer presented to the National Gene Therapy meeting in Brisbane
National Gene Therapy Meeting Recent findings for the progression of mRx-7 were presented at the Annual Joint Scientific Meeting hosted by the Australian Society for